Analysts predict that Nevro Corp. (NYSE:NVRO) will post ($0.23) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have made estimates for Nevro Corp.’s earnings, with the lowest EPS estimate coming in at ($0.39) and the highest estimate coming in at ($0.04). Nevro Corp. posted earnings per share of ($0.14) in the same quarter last year, which would indicate a negative year over year growth rate of 64.3%. The company is scheduled to issue its next quarterly earnings results after the market closes on Monday, November 6th.

According to Zacks, analysts expect that Nevro Corp. will report full-year earnings of ($1.20) per share for the current financial year, with EPS estimates ranging from ($1.43) to ($0.87). For the next fiscal year, analysts forecast that the business will report earnings of ($0.20) per share, with EPS estimates ranging from ($0.97) to $1.06. Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover Nevro Corp..

Nevro Corp. (NYSE:NVRO) last issued its quarterly earnings data on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.11). The company had revenue of $78.02 million for the quarter, compared to analysts’ expectations of $77.75 million. Nevro Corp. had a negative return on equity of 16.25% and a negative net margin of 14.33%. The company’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.31) earnings per share.

Several research analysts recently commented on the company. Zacks Investment Research raised Nevro Corp. from a “strong sell” rating to a “buy” rating and set a $96.00 target price for the company in a research note on Wednesday, August 2nd. Northland Securities reissued a “buy” rating and set a $96.00 target price on shares of Nevro Corp. in a research note on Tuesday, August 8th. BidaskClub cut Nevro Corp. from a “hold” rating to a “sell” rating in a research note on Saturday. J P Morgan Chase & Co reissued an “overweight” rating and set a $102.00 target price on shares of Nevro Corp. in a research note on Monday, July 3rd. Finally, Canaccord Genuity reissued a “buy” rating and set a $120.00 target price on shares of Nevro Corp. in a research note on Wednesday, July 5th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. Nevro Corp. currently has a consensus rating of “Hold” and a consensus target price of $101.25.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/30/zacks-analysts-expect-nevro-corp-nvro-to-announce-0-23-earnings-per-share.html.

In other Nevro Corp. news, Director Michael F. Demane sold 5,000 shares of Nevro Corp. stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $93.50, for a total transaction of $467,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew H. Galligan sold 7,000 shares of Nevro Corp. stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $82.31, for a total value of $576,170.00. The disclosure for this sale can be found here. Insiders have sold a total of 290,907 shares of company stock valued at $24,670,065 over the last ninety days. 12.10% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Hardman Johnston Global Advisors LLC lifted its holdings in Nevro Corp. by 1.1% during the 3rd quarter. Hardman Johnston Global Advisors LLC now owns 99,540 shares of the medical equipment provider’s stock worth $9,046,000 after buying an additional 1,050 shares during the last quarter. Fortaleza Asset Management Inc. lifted its holdings in Nevro Corp. by 47.7% during the 3rd quarter. Fortaleza Asset Management Inc. now owns 2,585 shares of the medical equipment provider’s stock worth $235,000 after buying an additional 835 shares during the last quarter. Pictet Asset Management Ltd. lifted its holdings in Nevro Corp. by 41.0% during the 3rd quarter. Pictet Asset Management Ltd. now owns 201,992 shares of the medical equipment provider’s stock worth $18,357,000 after buying an additional 58,738 shares during the last quarter. Tirschwell & Loewy Inc. lifted its holdings in Nevro Corp. by 113.2% during the 3rd quarter. Tirschwell & Loewy Inc. now owns 96,625 shares of the medical equipment provider’s stock worth $8,781,000 after buying an additional 51,295 shares during the last quarter. Finally, Strs Ohio lifted its holdings in Nevro Corp. by 1,982.3% during the 3rd quarter. Strs Ohio now owns 8,329 shares of the medical equipment provider’s stock worth $756,000 after buying an additional 7,929 shares during the last quarter.

Shares of Nevro Corp. (NYSE NVRO) traded down 0.73% during midday trading on Monday, hitting $86.51. The company had a trading volume of 383,841 shares. The company has a 50-day moving average of $89.94 and a 200 day moving average of $83.63. The firm’s market capitalization is $2.55 billion. Nevro Corp. has a 12 month low of $65.82 and a 12 month high of $99.63.

Nevro Corp. Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Get a free copy of the Zacks research report on Nevro Corp. (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.